BACKGROUND: HIV infection contributes to accelerated rates of progression of liver fibrosis during hepatitis C virus (HCV) infection, and HCV liver disease contributes to mortality during HIV infection. Although mechanisms underlying these interactions are not well known, soluble and cellular markers of immune activation associate with disease progression during both infections. METHODS: We identified proteins varying in expression across the plasma proteomes of subjects with untreated HIV infection, untreated HCV infection with low aspartate transaminase/platelet ratio index, untreated HCV infection with high aspartate transaminase/platelet ratio index, HIV-HCV coinfection, and controls. We examined correlations between dysregulated proteins and markers of immune activation to uncover biomarkers specific to disease states. RESULTS: We observed the anticipated higher frequencies of HLA-DRCD38CD4 and CD8 T cells, higher serum soluble CD14 levels, and higher serum interleukin-6 levels for HCV- and HIV-infected groups compared with controls. Plasma proteome analysis identified 2297 peptides mapping to 227 proteins, and quantitative analysis of peptide intensity identified significant changes in 85 proteins across the 5 groups. Abundance for 7 of these proteins was validated by enzyme-linked immunosorbent assay. Forty-three of these proteins correlated with markers of immune activation, including at least 2 proteins that may directly drive T-cell activation. As a functional validation, we tested the enzymatic pathway product (lysophosphatidic acid, LPA) of one such protein, ecotonucleotide pyrophosphatase/phosphodiesterase-2, for ability to activate T cells in vitro. LPA activated T cells to express CD38 and HLA-DR. CONCLUSIONS: These data indicate that elevated levels of ecotonucleotide pyrophosphatase/phosphodiesterase-2 and LPA during advanced HCV disease may play a role in exacerbating immune activation during HCV-HIV coinfection.
BACKGROUND:HIV infection contributes to accelerated rates of progression of liver fibrosis during hepatitis C virus (HCV) infection, and HCV liver disease contributes to mortality during HIV infection. Although mechanisms underlying these interactions are not well known, soluble and cellular markers of immune activation associate with disease progression during both infections. METHODS: We identified proteins varying in expression across the plasma proteomes of subjects with untreated HIV infection, untreated HCV infection with low aspartate transaminase/platelet ratio index, untreated HCV infection with high aspartate transaminase/platelet ratio index, HIV-HCV coinfection, and controls. We examined correlations between dysregulated proteins and markers of immune activation to uncover biomarkers specific to disease states. RESULTS: We observed the anticipated higher frequencies of HLA-DRCD38CD4 and CD8 T cells, higher serum soluble CD14 levels, and higher serum interleukin-6 levels for HCV- and HIV-infected groups compared with controls. Plasma proteome analysis identified 2297 peptides mapping to 227 proteins, and quantitative analysis of peptide intensity identified significant changes in 85 proteins across the 5 groups. Abundance for 7 of these proteins was validated by enzyme-linked immunosorbent assay. Forty-three of these proteins correlated with markers of immune activation, including at least 2 proteins that may directly drive T-cell activation. As a functional validation, we tested the enzymatic pathway product (lysophosphatidic acid, LPA) of one such protein, ecotonucleotide pyrophosphatase/phosphodiesterase-2, for ability to activate T cells in vitro. LPA activated T cells to express CD38 and HLA-DR. CONCLUSIONS: These data indicate that elevated levels of ecotonucleotide pyrophosphatase/phosphodiesterase-2 and LPA during advanced HCV disease may play a role in exacerbating immune activation during HCV-HIV coinfection.
Authors: Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley Journal: J Infect Dis Date: 2009-04-15 Impact factor: 5.226
Authors: Andrea Kovacs; Roksana Karim; Wendy J Mack; Jiaao Xu; Zhi Chen; Eva Operskalski; Toni Frederick; Alan Landay; John Voris; La Shonda Spencer; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Lena Al-Harthi Journal: J Infect Dis Date: 2010-03-15 Impact factor: 5.226
Authors: Daniela M Schlatzer; Jean-Eudes Dazard; Moyez Dharsee; Rob M Ewing; Serguei Ilchenko; Ian Stewart; George Christ; Mark R Chance Journal: Mol Cell Proteomics Date: 2009-06-04 Impact factor: 5.911
Authors: Hendrik Neubert; Timothy P Bonnert; Klaus Rumpel; Brandon T Hunt; Ernst S Henle; Ian T James Journal: J Proteome Res Date: 2008-04-16 Impact factor: 4.466
Authors: Eric Y Chan; Jennifer N Sutton; Jon M Jacobs; Andrey Bondarenko; Richard D Smith; Michael G Katze Journal: J Virol Date: 2009-07-08 Impact factor: 5.103
Authors: Lenche Kostadinova; Carey L Shive; Chelsey Judge; Elizabeth Zebrowski; Anita Compan; Kelsey Rife; Amy Hirsch; Yngve Falck-Ytter; Daniela M Schlatzer; Xiaolin Li; Mark R Chance; Benigno Rodriguez; Daniel L Popkin; Donald D Anthony Journal: J Infect Dis Date: 2016-08-17 Impact factor: 5.226
Authors: Carey L Shive; Chelsey J Judge; Brian Clagett; Robert C Kalayjian; Melissa Osborn; Kenneth E Sherman; Carl Fichtenbaum; Rajesh T Gandhi; Minhee Kang; Daniel L Popkin; Scott F Sieg; Michael M Lederman; Benigno Rodriguez; Donald D Anthony Journal: Vaccine Date: 2017-12-16 Impact factor: 4.169
Authors: Josep M Llibre; Pedro E Cahn; Janet Lo; Tristan J Barber; Cristina Mussini; Berend J van Welzen; Beatriz Hernandez; Cynthia Donovan; Michelle Kisare; Myooran Sithamparanathan; Jean van Wyk Journal: Open Forum Infect Dis Date: 2022-02-10 Impact factor: 3.835
Authors: Victoria L Brun; Amanda F Corbel; Ann W Hsing; Troy J Kemp; Alison L Van Dyke; Allan Hildesheim; Bin Zhu; Yu-Tang Gao; Ligia A Pinto; Jill Koshiol Journal: Sci Rep Date: 2021-06-28 Impact factor: 4.996
Authors: K V Shmagel; E V Saidakova; N G Shmagel; L B Korolevskaya; V A Chereshnev; J Robinson; J-C Grivel; D C Douek; L Margolis; D D Anthony; M M Lederman Journal: HIV Med Date: 2016-05-17 Impact factor: 3.094